House Democrats and Republicans are calling for more transparency on the details of the Trump administration’s deals with pharmaceutical companies, which President Donald Trump has touted as lowering prescription drug prices.
Members of the House Energy and Commerce Committee questioned pharmaceutical supply chain experts on Wednesday about whether President Donald Trump’s “Most Favored Nation” deals would lower prices that patients pay at the pharmacy counter.
Stay informed.Stay ahead.
Join Washington Examiner for unlimited access to the news, analysis, and commentary that matter most.
See Options
Already a member? Log in
Already a print subscriber? Click here to login/register your account
